首页> 外文期刊>BMC Cancer >Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report
【24h】

Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report

机译:患有遗传性平滑肌瘤病和肾细胞癌的高危个体的局部晚期2型乳头状肾细胞癌行根治性肾切除术和局部淋巴结清扫术:一例报告

获取原文
           

摘要

Background Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is an autosomal dominant tumor susceptibility syndrome, and the disease-related gene has been identified as fumarate hydratase (fumarase, FH ). HLRCC-associated kidney cancer is an aggressive tumor characterized by early metastasis to regional lymph nodes and distant organs. Since early diagnosis and provision of definitive therapy is thought to be the best way to reduce the tumor burden, it is widely accepted that germline testing and active surveillance for an at-risk individual from a family with HLRCC is very important. However, it still remains controversial how we should treat HLRCC-associated kidney cancer. We successfully treated the patient with locally advanced HLRCC-associated kidney cancer, who has received active surveillance because of at-risk individual, by radical nephrectomy and extended retroperitoneal lymph node dissection, and examined surgically resected samples from a molecular point of view. Case presentation We recommended that 13 at-risk individuals from a family with HLRCC should receive active surveillance for early detection of renal cancer. A 48-year-old woman with a left renal tumor and involvement of multiple regional lymph nodes with high accumulation of fluorine-18-deoxyglucose on positron emission tomography was treated with axitinib as a neoadjuvant therapy. Preoperative axitinib induced the shrinkage of the tumor with decreased fluorine-18-deoxyglucose accumulation. Resected samples showed two thirds tumor tissue necrosis as well as high expression of serine/threonine kinase Akt and low expression of nuclear factor E2-related factor 2 (Nrf2) which activates anti-oxidant response and protects against oxidative stress in viable cancer cells. Targeted next-generation sequencing revealed that FH mutation and loss of the second allele were completely identical between blood and tumor samples, suggesting that FH mutation plays a direct role in FH -deficient RCC. She has remained well after radical operation for over 33?months. Conclusions FH mutation plays a role in tumorigenic feature, a metabolic shift to aerobic glycolysis, and increased an anti-oxidant response phenotype in HLRCC-associated kidney cancer.
机译:背景遗传性平滑肌瘤病和肾细胞癌(HLRCC)是常染色体显性遗传易感性综合征,与疾病相关的基因已被鉴定为富马酸水合酶(fumarase,FH)。 HLRCC相关的肾癌是一种侵袭性肿瘤,其特征是早期转移到局部淋巴结和远处的器官。由于人们认为早期诊断和提供明确的治疗方法是减轻肿瘤负担的最佳方法,因此广泛接受的是,对于HLRCC家族中的高危个体,种系检测和积极监测非常重要。然而,如何治疗HLRCC相关的肾癌仍存在争议。我们通过根治性肾切除术和扩大的腹膜后淋巴结清扫术成功治疗了局部晚期HLRCC相关的肾癌患者,该患者因高危个体而受到了积极的监视,并从分子角度检查了手术切除的样本。病例介绍我们建议来自HLRCC家庭的13位高危个体应接受积极监测,以及早发现肾癌。阿昔替尼治疗了一名48岁的女性,该女性患有左肾肿瘤,并累及多个区域淋巴结,在正电子发射断层显像术中积累了大量氟18-脱氧葡萄糖,将其作为新辅助治疗。术前阿昔替尼诱导肿瘤缩小,氟18-脱氧葡萄糖积累减少。切除的样本显示三分之二的肿瘤组织坏死以及丝氨酸/苏氨酸激酶Akt的高表达和核因子E2相关因子2(Nrf2)的低表达,它们激活了抗氧化反应并保护了存活癌细胞中的氧化应激。靶向的下一代测序表明,血液和肿瘤样品之间的FH突变和第二个等位基因的缺失完全相同,这表明FH突变在FH缺陷型RCC中起直接作用。经过33个月的彻底手术,她一直保持良好状态。结论FH突变在HLRCC相关的肾癌中具有致癌性,代谢转移至有氧糖酵解并增加抗氧化反应表型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号